MEDIA

Media Inquiries

Investors@OncoSec.com

855-662-6732

Press Releases

VIEW ALL PRESS RELEASES

Video Feed

3D MOA Animation video

✕

OncoSec's VLA 3D MOA Animation

✕

TAVO Demonstration with Dr Algazi

✕

OncoSec at 2020 BIO CEO Panel

✕

Tumor Immunogenicity

✕

IAD Reel

✕

IAD Robert Andtbacka, M.D.

✕

Social Media

Twitter Feed

OncoSec Medical@OncoSec·
3 Dec

Join us in supporting @CureMelanoma's virtual fundraising gala tonight! We extend our gratitude to MRF & appreciate the impactful work they do to transform the treatment of #melanoma for patients, families & care partners. Learn how to participate/donate: http://bit.ly/32SoAKB

OncoSec Medical@OncoSec·
23 Nov

November is #NationalHealthySkin Month. At OncoSec we're focused on developing an effective alternative for those patients suffering from #MetastaticMelanoma. Learn more: http://bit.ly/3oz1WjC #TogetherAgainstCancer

OncoSec Medical@OncoSec·
18 Nov

Our #COVID19 #DNAVaccine is the 8th to enter clinical trials in the US. Check out this @nytimes vaccine tracker to learn about our approach, which combines IL-12 w/ the spike protein to potentially optimize immune responses & protect vulnerable patients: http://nyti.ms/36QGMFI

OncoSec Medical@OncoSec·
18 Nov

It's National Family Caregivers Month! At OncoSec, we are committed to supporting the #caregivers who ensure your loved ones and their extended support community are taken care of everyday.

Featured Articles

Melanoma Research Alliance

From Dermatology to Treatment: Second Opinions, Clinical Trials & becoming Your Own Best Advocate

PharmaVoice

Women of the Week interview with OncoSec’s Chief Clinical Development Officer, Kellie Malloy Foerter

Annals of Oncology

Intratumoral delivery of tavokinogene telseplasmid yields systemic immune responses in metastatic melanoma patients

Clinical Cancer Research

Intratumoral Delivery of Plasmid IL12 Via Electroporation Leads to Regression of Injected and Noninjected Tumors in Merkel Cell Carcinoma.